植物衍生化合物作为帕金森病潜在的神经保护剂
Chengu Niu1, Yu Zou2, Miaoxian Dong3
1Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY 14621, USA.
Nutrition (Burbank, Los Angeles County, Calif.)
|November 15, 2024
概括
植物化学物质通过向氧化应激,神经炎症和线粒体功能障碍来减缓帕金森病 (PD) 的进展. 需要进一步的研究来将这些神经保护性发现从临床前研究转化为帕金森病的临床应用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 目前的帕金森病 (PD) 治疗方法可以控制症状,但不能阻止疾病的进展,这凸显了对疾病修饰疗法的未满足需求.
- 氧化应激,神经炎症和线粒体功能障碍是关键的病理机制,涉及帕金森病的发病因子.
研究的目的:
- 审查最近关于植物化学品在治疗帕金森病中的疗效的研究结果.
- 在PD的临床前模型中阐明植物化学作用的潜在机制.
主要方法:
- 使用PubMed从创立到2024年1月进行了全面的文献搜索.
- 该综述综合了临床前关于植物化学品的数据,这些植物化学品针对PD的氧化应激,神经炎症和线粒体功能障碍.
主要成果:
- 植物化学物质在PD的临床前模型中显示出抗氧化,抗炎和线粒体保护作用.
- 有证据表明,植物化学物质可以减轻参与帕金森病进展的关键病理过程.
结论:
- 广泛的临床前证据支持神经保护性植物化学物质作为帕金森病治疗的有希望的候选者.
- 将这些有希望的临床前发现转化为有效的帕金森病临床治疗仍然是一个关键的挑战.
相关概念视频
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K


